MSc.Mol & Biot, BTch. of technology and laboratory science(BTECH-LS)// Dip.of Biotechnology// formal DITSO president// good citzen// patriot of Tz// scientist
Through a pair of recent clinical milestones, Kymera Therapeutics continues to cash in on its up-to-$2 billion collaboration with Sanofi to develop first-in-class targeted protein degradation (TPD) therapies for patients with immune-inflammatory diseases. https://t.co/XJ9GXF1VV4